MADDEN SECURITIES Corp Reduces Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

MADDEN SECURITIES Corp reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 21,840 shares of the biopharmaceutical company’s stock after selling 400 shares during the period. MADDEN SECURITIES Corp’s holdings in Gilead Sciences were worth $1,831,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Livforsakringsbolaget Skandia Omsesidigt increased its stake in Gilead Sciences by 398.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 10,717 shares of the biopharmaceutical company’s stock valued at $898,000 after purchasing an additional 8,565 shares during the period. Juncture Wealth Strategies LLC increased its position in Gilead Sciences by 20.2% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 8,525 shares of the biopharmaceutical company’s stock valued at $715,000 after acquiring an additional 1,433 shares during the period. West Coast Financial LLC purchased a new stake in Gilead Sciences during the 3rd quarter valued at approximately $367,000. LVW Advisors LLC lifted its position in Gilead Sciences by 11.5% during the 3rd quarter. LVW Advisors LLC now owns 18,819 shares of the biopharmaceutical company’s stock worth $1,578,000 after acquiring an additional 1,939 shares during the period. Finally, Successful Portfolios LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at approximately $202,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on GILD shares. Barclays lifted their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Cantor Fitzgerald reissued a “neutral” rating and set a $70.00 target price on shares of Gilead Sciences in a research note on Monday, September 16th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler restated an “overweight” rating and set a $95.00 target price on shares of Gilead Sciences in a research report on Wednesday, September 11th. Ten research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $84.83.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,847 shares of company stock worth $3,033,340. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Up 0.3 %

GILD stock opened at $84.95 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The firm’s 50-day simple moving average is $79.87 and its 200 day simple moving average is $72.34. The stock has a market cap of $105.76 billion, a PE ratio of 103.60, a price-to-earnings-growth ratio of 2.98 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The company had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.63%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s payout ratio is currently 375.61%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.